Journal of Clinical Endocrinology & Metabolism, Vol 74, 1032-1035, Copyright © 1992 by Endocrine Society

ARTICLES

Very high concentrations of islet amyloid polypeptide are necessary to alter the insulin response to intravenous glucose in man

D Bretherton-Watt, SG Gilbey, MA Ghatei, J Beacham, AD Macrae and SR Bloom
Department of Medicine, Royal Postgraduate Medical School, London, United Kingdom.

Islet amyloid polypeptide (IAPP) is a beta-cell peptide that can oppose insulin action in animal systems, but has not been shown to have any action in man; previously, we failed to show an effect of infused IAPP on iv glucose tolerance in human volunteers. We have reexamined its effects at even higher concentrations in six volunteers who received iv glucose (0.5 g/kg) during infusions of IAPP (25 and 50 pmol/kg.min) or normal saline. IAPP rose from a mean basal of 14.7 +/- 5.3 pmol/L to peak levels of 1,420 +/- 110, 2,240 +/- 140, and 27.7 +/- 9 pmol/L, respectively. IAPP at 25 pmol/kg.min had no effect on the plasma glucose disposal rate or the total incremental insulin response, but, in contrast, at 50 pmol/kg.min decreased the insulin response to glucose compared to the saline infusion (incremental area under the curve, 11,276 +/- 2,353 vs. 17,549 +/- 2,687 U; mean +/- SEM; P less than 0.02). This decrease was observed both during the first phase (0- 10 min postglucose) insulin response (3,210 +/- 985 vs. 4,382 +/- 815 U; P less than 0.05) and the second phase response (11-90 min, 8,520 +/- 1,719 vs. 13,679 +/- 2,326 U; P less than 0.03). Glucose disposal rate, however, was unaffected (2.0 +/- 0.2 vs. 1.9 +/- 0.2). Thus, circulating IAPP concentrations greater than 90 times normal postprandial peaks were necessary to affect the insulin response to glucose. IAPP appears unlikely to be a circulating hormone influencing carbohydrate metabolism in man.

This article has been cited by other articles:

				O. Schmitz, B. Brock, and J. Rungby Amylin Agonists: A Novel Approach in the Treatment of Diabetes Diabetes, December 1, 2004; 53(suppl_3): S233 - S238. [Abstract] [Full Text] [PDF]

				M. Clodi, K. Thomaseth, G. Pacini, K. Hermann, A. Kautzky-Willer, W. Waldhausl, R. Prager, and B. Ludvik Distribution and kinetics of amylin in humans Am J Physiol Endocrinol Metab, May 1, 1998; 274(5): E903 - E908. [Abstract] [Full Text] [PDF]

				U. Arnelo, J. Permert, J. Larsson, R. D. Reidelberger, C. Arnelo, and T. E. Adrian Chronic Low Dose Islet Amyloid Polypeptide Infusion Reduces Food Intake, But Does Not Influence Glucose Metabolism, in Unrestrained Conscious Rats: Studies Using a Novel Aortic Catheterization Technique Endocrinology, October 1, 1997; 138(10): 4081 - 4085. [Abstract] [Full Text] [PDF]

				M. E. Cooper, P. G. McNally, P. A. Phillips, and C. I. Johnston Amylin Stimulates Plasma Renin Concentration in Humans Hypertension, September 1, 1995; 26(3): 460 - 464. [Abstract] [Full Text]

				J. Permert, J. Larsson, G. T. Westermark, M. K. Herrington, L. Christmanson, P. M. Pour, P. Westermark, and T. E. Adrian Islet Amyloid Polypeptide in Patients with Pancreatic Cancer and Diabetes N. Engl. J. Med., February 3, 1994; 330(5): 313 - 318. [Abstract] [Full Text]